regulation is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention ANKTIVA, the most common co-covered peer. Each story carries 2 original sources on average, compared with 3.3 for the broader beat in this window.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Macau Health Bureau
regulation is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention ANKTIVA, the most common co-covered peer. Each story carries 2 original sources on average, compared with 3.3 for the broader beat in this window. At 7, the average consequence score sits above the same-window beat average of 6.6. We currently track 1 Healthcare story that mention Macau Health Bureau, all published on March 25, 2026.
Stories tracked
1
Sources per story
2
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 26 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Macau Health Bureau. Shared-story counts are live from our verified record — not editorial picks.
ImmunityBio Inc. has received regulatory approval for its flagship immunotherapy, ANKTIVA, in the Macau Special Administrative Region of China. This milestone marks the first international expansion for the IL-15 superagonist following its 2024 U.S. FDA approval, positioning the company to tap into the significant oncology market in the Greater Bay Area.